Bayer and Azitra have announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases.
Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future license agreement. Prospective areas of application include medicated skin care products for sensitive, eczema-prone skin as well as therapeutic products for skin diseases such as atopic dermatitis. more